D.A. Davidson & CO. Has $81.22 Million Holdings in Amgen Inc. $AMGN

Key Points

• D.A. Davidson & CO. raised its Amgen stake to 248,154 shares worth $81.22 million (a 2.1% increase), and about 76.5% of Amgen is owned by institutional investors.
• Amgen completed an early Phase 1/2 MTAP‑null cancer combination study, a clinical milestone for its oncology pipeline, but pre‑earnings previews point to a possible Q1 EPS decline ahead of the company's April 30 results, a near‑term volatility driver.
• Multiple brokerages have boosted price targets (some into the $390–$432 range) and ratings, yet the MarketBeat consensus remains a “Hold” with a $356.62 target.

D.A. Davidson & CO. raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 248,154 shares of the medical research company's stock after buying an additional 5,100 shares during the quarter. D.A. Davidson & CO.'s holdings in Amgen were worth $81,224,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Capital World Investors lifted its stake in Amgen by 11.5% in the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the period. Vanguard Group Inc. lifted its stake in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after buying an additional 961,975 shares during the period. National Bank of Canada FI lifted its stake in Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock valued at $346,076,000 after buying an additional 863,216 shares during the period. Van ECK Associates Corp lifted its stake in Amgen by 71.8% in the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock valued at $383,254,000 after buying an additional 567,400 shares during the period. Finally, Fisher Asset Management LLC lifted its stake in Amgen by 91.6% in the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock valued at $221,607,000 after buying an additional 375,463 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported completion of an early Phase 1/2 MTAP‑null cancer combination study — a clinical milestone that can de‑risk a development program and supports longer‑term oncology pipeline value. Company Study Completion
• Positive Sentiment: Guggenheim nudged its price target on AMGN to $351 (maintaining a Neutral rating), which signals modest analyst upside versus the stock’s trading range and can provide short‑term support. Guggenheim PT Update
• Neutral Sentiment: Amgen confirmed it will report Q1 2026 results after the market close on April 30 and will host a webcast — an obvious near‑term volatility driver as investors adjust positions into the print. Q1 Webcast
• Neutral Sentiment: Legislation (H.R. 8203) expanding workforce and treatment funding for substance use disorders was introduced; Amgen is listed among relevant healthcare companies — this is a longer‑horizon policy item that could modestly affect labor/training dynamics but is unlikely to move the stock immediately. H.R.8203 Bill
• Negative Sentiment: Pre‑earnings previews from Zacks and Yahoo Finance suggest AMGN may report a decline in Q1 earnings (reducing the odds of an earnings beat), which increases downside risk into the report. Earnings Preview
• Negative Sentiment: Insiders sold roughly US$4.1M of Amgen stock over the past year — sizable insider selling can be perceived as a cautionary signal by some investors. Insider Selling
• Neutral Sentiment: Amgen announced the planned retirement of EVP & Chief Technology Officer David M. Reese effective June 30, 2026, with a strategic leadership realignment — a governance event to watch, but presented as orderly and planned. CTO Retirement

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMGN. UBS Group boosted their price target on Amgen from $390.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, April 13th. Daiwa Securities Group boosted their price target on Amgen from $370.00 to $410.00 and gave the company an "outperform" rating in a research note on Tuesday, February 10th. Piper Sandler boosted their price objective on Amgen from $381.00 to $432.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Mizuho boosted their price objective on Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. Finally, Citigroup boosted their price objective on Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of "Hold" and a consensus target price of $356.62.

Amgen Stock Performance

NASDAQ AMGN opened at $344.55 on Monday. The company has a market cap of $185.95 billion, a price-to-earnings ratio of 24.21, a P/E/G ratio of 3.60 and a beta of 0.47. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The business has a 50 day moving average price of $360.74 and a 200-day moving average price of $339.77. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company's quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.16 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen's dividend payout ratio is 70.84%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.